Mostrar el registro sencillo del ítem
Evaluation of Two Chemiluminescent and Three ELISA Immunoassays for the Detection of SARS-CoV-2 IgG Antibodies: Implications for Disease Diagnosis and Patients’ Management
dc.creator | Speletas M., Kyritsi M.A., Vontas A., Theodoridou A., Chrysanthidis T., Hatzianastasiou S., Petinaki E., Hadjichristodoulou C., the COGESE study group | en |
dc.date.accessioned | 2023-01-31T10:01:12Z | |
dc.date.available | 2023-01-31T10:01:12Z | |
dc.date.issued | 2020 | |
dc.identifier | 10.3389/fimmu.2020.609242 | |
dc.identifier.issn | 16643224 | |
dc.identifier.uri | http://hdl.handle.net/11615/79323 | |
dc.description.abstract | The estimation of anti-SARS-CoV-2 IgG antibodies is possibly the best approach to accurately establish the number of infected individuals and the seroprevalence of COVID-19 within a population. Thus, several commercial immunoassays have recently been developed. The purpose of our study was to assess the performance of five commonly used immunoassays in Greece (3 ELISA, namely Euroimmun SARS-CoV-2, GA GENERIC SARS-CoV-2 and Vircell COVID-19; and 2 chemiluminescent, namely ABBOTT SARS-CoV-2 and ROCHE Elecsys Anti-SARS-CoV-2 test) for the detection of anti-SARS-CoV-2 IgG antibodies. Sera specimens derived from 168 individuals were utilized to assess the specificity and sensitivity score of each assay. Among them, we included 99 COVID-19 patients (29 asymptomatic, 36 with symptom onset 4 to 14 days before serum sampling, and 34 with symptom initiation ≥ 15 days ago), and 69 volunteers with sera specimens collected prior to the SARS-CoV-2 outbreak and maintained at −80°C. We demonstrated that chemiluminescent immunoassays exhibit a significantly higher specificity score but a lower sensitivity, compared to ELISA immunoassays. Moreover, immunoassays detecting IgG antibodies against SARS-CoV-2 N protein instead of S protein alone are more reliable, considering both specificity and sensitivity scores. Interestingly, all asymptomatic patients displayed anti-SARS-CoV-2 IgG antibodies, confirmed by at least two immunoassays. We suggest that chemiluminescent assays could be used as screening methods for the detection of anti-SARS-CoV-2 antibodies to evaluate the possible prevalence of disease in the general population, while ELISA assays would be more reliable to evaluate, and follow-up confirmed COVID-19 patients. © Copyright © 2020 Speletas, Kyritsi, Vontas, Theodoridou, Chrysanthidis, Hatzianastasiou, Petinaki and Hadjichristodoulou. | en |
dc.language.iso | en | en |
dc.source | Frontiers in Immunology | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85099026123&doi=10.3389%2ffimmu.2020.609242&partnerID=40&md5=09d98b4e7a6c5eeb69cf408353a6f553 | |
dc.subject | immunoglobulin A | en |
dc.subject | immunoglobulin G | en |
dc.subject | immunoglobulin G antibody | en |
dc.subject | immunoglobulin M | en |
dc.subject | SARS-CoV-2 antibody | en |
dc.subject | immunoglobulin G | en |
dc.subject | virus antibody | en |
dc.subject | adult | en |
dc.subject | antibody response | en |
dc.subject | Article | en |
dc.subject | chemoluminescence | en |
dc.subject | controlled study | en |
dc.subject | coronavirus disease 2019 | en |
dc.subject | cross-sectional study | en |
dc.subject | diagnostic accuracy | en |
dc.subject | diagnostic test accuracy study | en |
dc.subject | disease transmission | en |
dc.subject | electrochemiluminescence | en |
dc.subject | enzyme linked immunosorbent assay | en |
dc.subject | female | en |
dc.subject | follow up | en |
dc.subject | human | en |
dc.subject | human tissue | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | middle aged | en |
dc.subject | predictive value | en |
dc.subject | prevalence | en |
dc.subject | receiver operating characteristic | en |
dc.subject | sensitivity and specificity | en |
dc.subject | seroprevalence | en |
dc.subject | blood | en |
dc.subject | comparative study | en |
dc.subject | diagnosis | en |
dc.subject | epidemiology | en |
dc.subject | immunoassay | en |
dc.subject | immunology | en |
dc.subject | luminescence | en |
dc.subject | seroepidemiology | en |
dc.subject | virology | en |
dc.subject | Antibodies, Viral | en |
dc.subject | COVID-19 | en |
dc.subject | COVID-19 Testing | en |
dc.subject | Humans | en |
dc.subject | Immunoassay | en |
dc.subject | Immunoglobulin G | en |
dc.subject | Luminescent Measurements | en |
dc.subject | SARS-CoV-2 | en |
dc.subject | Sensitivity and Specificity | en |
dc.subject | Seroepidemiologic Studies | en |
dc.subject | Frontiers Media S.A. | en |
dc.title | Evaluation of Two Chemiluminescent and Three ELISA Immunoassays for the Detection of SARS-CoV-2 IgG Antibodies: Implications for Disease Diagnosis and Patients’ Management | en |
dc.type | journalArticle | en |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |